Skip to content
Home
About Us
Longevity Platform
Bio101
BIO101 in Sarcopenia
BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
Posters & Publications
Scientific Press Releases
Recruitment
Investors
Stock Information
Corporate Presentation
Letter to shareholders
Press Releases
General Meetings
AMF Regulated Information
SEC Filings
Convertible bonds
Pre-financed vouchers (PFW)
Obligations Hexagon
Contact for Investors
Contact
EN
FR
Blog Category
May 12, 2021
Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis
Press Releases
,
Scientific
/
12 May 2021
Go to Top
Home
About Us
Longevity Platform
Bio101
BIO101 in Sarcopenia
BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
Posters & Publications
Scientific Press Releases
Recruitment
Investors
Stock Information
Corporate Presentation
Letter to shareholders
Press Releases
General Meetings
AMF Regulated Information
SEC Filings
Convertible bonds
Pre-financed vouchers (PFW)
Obligations Hexagon
Contact for Investors
Contact
EN
FR